Astellas establishes Regenerative Medicine Unit

Published: 2-Apr-2014
Research & Development Pharmaceutical Cell & Gene Therapy

Will expand the company\'s research into regenerative medicine and cell therapy


Japanese pharmaceutical company Astellas has announced the launch of its new regenerative medicine business unit, which commenced operations on 1 April.

The new division aims to undertake innovative regenerative medicine studies and build an autonomous and highly agile research management structure, reporting directly to Astellas' Senior Vice-President and President of drug discovery research.

Its key priorities will be to establish and maintain technology platforms involving regenerative medicine and cell therapy, taking advantage of the multifunctional characteristics of cells to produce more effective treatments than are currently available.

Astellas stated last year that it would expand its presence in the regenerative medicine field, with its new cell therapy focus coming in addition to the conventional pharmaceutical research that it undertakes.

  • Companies:
  • Astellas Pharma
See more

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

Read more
The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone

Trending Articles

  1. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms
  2. Thermo Fisher Scientific reveals MagMax Sequential DNA/RNA Kit to advance blood cancer research The kit combines DNA and RNA isolation chemistries into a single kit, simplifying sample extraction for a broad range of downstream molecular applications
  3. Lessons learned: AstraZeneca’s supply chain resilience during the pandemic With 26 manufacturing facilities and a global network of more than 250 suppliers, AstraZeneca’s Global Operations Manufacturing footprint is not only large in scale, it's also highly complex and positioned to deliver medicines to patients worldwide
  4. Medac and chiron develop organ-on chip tech for animal free drug testing The companies aim to develop an animal-free pharmaceutical testing method that utilises organ-on chip technology, and will be used in rheumatoid arthritis drug testing
  5. Asahi Kasei Pharma grows its global portfolio with anti-CX3CR1 license The licensing deal with Chiome enhances its open innovation platform

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Regulatory

Astellas' Vyloytm plus chemo gains FDA approval for gastric adenocarcinoma

The drug is the first CLDN18.2 targeted therapy to be approved in the US, and can further extend a patient's PFS and OS compared with chemotherapy alone
Research & Development

Astellas Pharma doses first patient in Phase III trial for Fezolinetant

Fezolinetant aims to mitigate the impact of hot flushes, which are the most common side effect associated with endocrine therapy for breast cancer
Manufacturing

Astellas begins construction of manufacturing site in Tralee

600 construction jobs and 100 specialised engineering, science and technology roles will be created from the project
Regulatory

Ubiquigent enters agreement with Astellas subsidiary, Nanna Therapeutics

Agreement leverages Ubiquigent’s DUB-focused drug discovery platform to support the development of novel therapeutic candidates for multiple disease targets selected by Nanna Therapeutics
Ingredients

Therapeutic: zolbetuximab for gastric cancer

Stomach cancer is the fifth most commonly diagnosed form of cancer, with risk factors including age, smoking, H. pylori infection and gastro-oesophageal reflux disease
Research & Development

Astellas invests $13m in cell and gene therapy innovation incubators

Japanese Astellas’ nearly $13m will make it a Founding Sponsor of LabCentral's new incubator with a core lab space for process development studies and a non-GMP pilot plant
Finance

Astellas to buy Ocata Therapeutics

New step forward in ophthalmology and stem cell therapy
Subscribe now